CU24208B1 - Sal de diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y método de preparación de la misma - Google Patents

Sal de diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y método de preparación de la misma

Info

Publication number
CU24208B1
CU24208B1 CUP2013000133A CU20130133A CU24208B1 CU 24208 B1 CU24208 B1 CU 24208B1 CU P2013000133 A CUP2013000133 A CU P2013000133A CU 20130133 A CU20130133 A CU 20130133A CU 24208 B1 CU24208 B1 CU 24208B1
Authority
CU
Cuba
Prior art keywords
dihydroimidazo
quinazolin
amino
ilpropoxi
diclorhydrate
Prior art date
Application number
CUP2013000133A
Other languages
English (en)
Spanish (es)
Other versions
CU20130133A7 (es
Inventor
Jan Georg Peters
Hans-Christian Militzer
Hartwig Müller
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43984137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24208(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20130133A7 publication Critical patent/CU20130133A7/es
Publication of CU24208B1 publication Critical patent/CU24208B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CUP2013000133A 2011-04-05 2012-03-29 Sal de diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y método de preparación de la misma CU24208B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11161111A EP2508525A1 (en) 2011-04-05 2011-04-05 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
PCT/EP2012/055600 WO2012136553A1 (en) 2011-04-05 2012-03-29 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Publications (2)

Publication Number Publication Date
CU20130133A7 CU20130133A7 (es) 2014-01-29
CU24208B1 true CU24208B1 (es) 2016-11-29

Family

ID=43984137

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2013000133A CU24208B1 (es) 2011-04-05 2012-03-29 Sal de diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y método de preparación de la misma

Country Status (42)

Country Link
US (2) US10383876B2 (zh)
EP (2) EP2508525A1 (zh)
JP (2) JP5763834B2 (zh)
KR (1) KR101937501B1 (zh)
CN (1) CN103649091B (zh)
AP (1) AP3709A (zh)
AR (1) AR085718A1 (zh)
AU (1) AU2012238891B2 (zh)
BR (1) BR112013025549A2 (zh)
CA (1) CA2832123C (zh)
CL (1) CL2013002870A1 (zh)
CO (1) CO6781534A2 (zh)
CR (1) CR20130511A (zh)
CU (1) CU24208B1 (zh)
CY (1) CY1116231T1 (zh)
DK (1) DK2694508T3 (zh)
DO (1) DOP2013000223A (zh)
EA (1) EA023646B1 (zh)
EC (1) ECSP13013006A (zh)
ES (1) ES2529653T3 (zh)
GT (1) GT201300234A (zh)
HR (1) HRP20150138T1 (zh)
IL (1) IL228561A (zh)
JO (1) JO2958B1 (zh)
MA (1) MA35014B1 (zh)
ME (1) ME02021B (zh)
MX (1) MX336057B (zh)
MY (1) MY169452A (zh)
PE (1) PE20141038A1 (zh)
PH (1) PH12013502065A1 (zh)
PL (1) PL2694508T3 (zh)
PT (1) PT2694508E (zh)
RS (1) RS53811B1 (zh)
SG (1) SG193595A1 (zh)
SI (1) SI2694508T1 (zh)
SM (1) SMT201500037B (zh)
TN (1) TN2013000401A1 (zh)
TW (2) TWI549954B (zh)
UA (1) UA111604C2 (zh)
UY (1) UY33985A (zh)
WO (1) WO2012136553A1 (zh)
ZA (1) ZA201307105B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
MX2015014171A (es) * 2013-04-08 2015-12-16 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas.
SG11201509116VA (en) 2013-06-14 2015-12-30 Bayer Pharma AG Anti-tweakr antibodies and uses thereof
CN103694319B (zh) * 2013-12-20 2018-02-27 深圳翰宇药业股份有限公司 一种布舍瑞林的纯化方法
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
AU2016231260A1 (en) * 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
PT3274370T (pt) 2015-03-23 2020-01-30 Bayer Pharma AG Anticorpos anti-ceacam6 e utilizações dos mesmos
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
MX2018009368A (es) 2016-02-01 2018-09-05 Bayer Pharma AG Biomarcadores para copanlisib.
AU2017215096A1 (en) 2016-02-01 2018-08-09 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
CA3016584A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
CN109729716B (zh) 2016-09-23 2022-03-15 拜耳制药股份公司 Pi3k-抑制剂的组合产品
US11241500B2 (en) 2016-12-14 2022-02-08 Tarveda Therapeutics, Inc. HSP90-targeting conjugates and formulations thereof
US11684672B2 (en) 2017-02-24 2023-06-27 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-PD-1 antibody
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
EP3498266A1 (en) 2017-12-15 2019-06-19 Bayer Consumer Care AG Formulations of copanlisib
JP2020533292A (ja) 2017-09-08 2020-11-19 バイエル・コンシューマー・ケア・アクチェンゲゼルシャフトＢａｙｅｒ Ｃｏｎｓｕｍｅｒ Ｃａｒｅ ＡＧ コパンリシブの製剤
WO2019105734A1 (en) 2017-11-28 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib
WO2019105835A1 (en) 2017-11-29 2019-06-06 Bayer Consumer Care Ag Combinations of copanlisib and anetumab ravtansine
WO2019197269A1 (en) 2018-04-11 2019-10-17 Bayer Aktiengesellschaft Combinations of copanlisib with triazolone derivatives and their use in the treatment of cancer
EP3843743A1 (en) 2018-08-28 2021-07-07 Bayer AS Combination of pi3k-inhibitors and targeted thorium conjugates
EP3866805A1 (en) * 2018-10-16 2021-08-25 Bayer Aktiengesellschaft Combination of atr kinase inhibitors with 2,3-dihydroimidazo[1,2-c]quinazoline compounds
EP3866923A1 (en) * 2018-10-17 2021-08-25 Sandoz AG Co-crystals comprising levothyroxine and a dicarboxylic acid
AU2019416623B2 (en) * 2018-12-27 2022-12-08 Holosmedic Novel compound and pharmaceutical composition comprising same for enhancing anticancer activity
WO2020164997A1 (en) 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023218032A1 (en) 2022-05-13 2023-11-16 Synthon B.V. Solid forms of copanlisib salts
WO2025053315A1 (ko) * 2023-09-08 2025-03-13 파로스젠 주식회사 항암제 프로드러그 컨쥬게이트의 제조에서 팔라듐의 회수 및 제거 방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH605550A5 (zh) 1972-06-08 1978-09-29 Research Corp
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (zh) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
UA82205C2 (en) * 2002-09-30 2008-03-25 Байер Фармасьютикалз Корпорейшн Fused azole-pyrimidine derivatives
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
CA2713388C (en) * 2008-01-14 2016-03-29 William Scott Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
EP2168582A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Combinations of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
PH12012502069A1 (en) 2010-04-16 2013-02-04 Bayer Ip Gmbh Substituted 2,3-dihydroimidazo [1,2-c] quinazoline - containing combinations
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
MX2015014171A (es) 2013-04-08 2015-12-16 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas.
WO2015082322A1 (en) 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft COMBINATION of PI3K-INHIBITORS
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
JP6867295B2 (ja) 2015-03-09 2021-04-28 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリンを含んでいる組合せ
AU2016231260A1 (en) * 2015-03-09 2017-09-21 Bayer Healthcare Pharmaceuticals Inc. Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines

Also Published As

Publication number Publication date
TWI549954B (zh) 2016-09-21
IL228561A0 (en) 2013-12-31
TWI592158B (zh) 2017-07-21
SG193595A1 (en) 2013-10-30
EP2508525A1 (en) 2012-10-10
PE20141038A1 (es) 2014-09-05
KR101937501B1 (ko) 2019-01-10
AU2012238891A1 (en) 2013-10-24
ME02021B (me) 2015-05-20
WO2012136553A1 (en) 2012-10-11
JP5826961B2 (ja) 2015-12-02
EP2694508B1 (en) 2014-11-19
IL228561A (en) 2015-10-29
EA023646B1 (ru) 2016-06-30
PT2694508E (pt) 2015-02-10
UA111604C2 (uk) 2016-05-25
PL2694508T3 (pl) 2015-04-30
CN103649091B (zh) 2016-06-22
CL2013002870A1 (es) 2014-06-20
AU2012238891B2 (en) 2016-12-01
US9636344B2 (en) 2017-05-02
SI2694508T1 (sl) 2015-03-31
HRP20150138T1 (hr) 2015-05-08
CR20130511A (es) 2013-12-04
TN2013000401A1 (en) 2015-03-30
ZA201307105B (en) 2014-11-26
CA2832123A1 (en) 2012-10-11
CA2832123C (en) 2018-09-11
EA201391470A1 (ru) 2014-03-31
CY1116231T1 (el) 2017-02-08
MY169452A (en) 2019-04-11
BR112013025549A2 (pt) 2016-12-27
CO6781534A2 (es) 2013-10-31
AR085718A1 (es) 2013-10-23
EP2694508A1 (en) 2014-02-12
PH12013502065A1 (en) 2016-06-29
GT201300234A (es) 2015-01-16
JP5763834B2 (ja) 2015-08-12
AP2013007219A0 (en) 2013-10-31
AP3709A (en) 2016-05-31
MA35014B1 (fr) 2014-04-03
TW201249847A (en) 2012-12-16
ECSP13013006A (es) 2013-12-31
TW201637656A (zh) 2016-11-01
CN103649091A (zh) 2014-03-19
NZ616198A (en) 2015-09-25
MX336057B (es) 2016-01-07
RS53811B1 (sr) 2015-06-30
MX2013011583A (es) 2013-12-16
JP2015164936A (ja) 2015-09-17
HK1195907A1 (zh) 2014-11-28
KR20140021637A (ko) 2014-02-20
DOP2013000223A (es) 2013-11-15
US20140072529A1 (en) 2014-03-13
SMT201500037B (it) 2015-05-05
US10383876B2 (en) 2019-08-20
US20160193219A1 (en) 2016-07-07
JO2958B1 (en) 2016-03-15
CU20130133A7 (es) 2014-01-29
UY33985A (es) 2012-10-31
JP2014510119A (ja) 2014-04-24
ES2529653T3 (es) 2015-02-24
DK2694508T3 (en) 2015-02-16

Similar Documents

Publication Publication Date Title
CU24208B1 (es) Sal de diclorhidrato de 2-amino-n-[7-metoxi-8-(3-morfolin-4-ilpropoxi)-2,3-dihidroimidazo-[1,2-c]quinazolin-5-il]pirimidin-5-carboxamida y método de preparación de la misma
UA116920C2 (uk) Інгібітори fgfr4
EA201492165A1 (ru) Синтез пирроло[2,3-b]пиридинов
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
EA201691121A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201270149A1 (ru) Ингибиторы bace
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
IL231378A0 (en) Cannula tips, tissue attachment rings, and methods of delivering and using the same
BR112013021134A2 (pt) moduladores e métodos de uso
MX2014001885A (es) Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona.
BR112013028966A2 (pt) sistema fotobiorreator de calha em v e método de uso
UA110626C2 (uk) Спосіб одержання пан-інгібіторів циклінзалежної кінази формули (i), а також проміжні продукти цього процесу одержання
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201491303A1 (ru) Конденсированные тетра- или пентациклические дигидродиазепинокарбазолоны в качестве ингибиторов parps
EA201201357A1 (ru) Антитела к cd40
EA201290988A1 (ru) Стереоселективный синтез фосфорсодержащих активных соединений
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
EA201270350A1 (ru) Способ идентификации и получения (r)-специфической омега-трансаминазы
HK1213471A1 (zh) 作為蛋白脫乙酰基酶抑制劑的嘧啶羥基酰胺化合物及其使用方法
PH12018501404A1 (en) Forms of rifaximin and uses thereof
EA201300871A1 (ru) ПРОИЗВОДНЫЕ (1,2,4)ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗ
MX377904B (es) Preparacion de derivados de hidroxi - bencilbenceno.
EP2563795A4 (en) Inhibitors of protein intolerance activity
UY34314A (es) Derivados de anilina, su preparación y su aplicación terapéutica.
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу

Legal Events

Date Code Title Description
FG Grant of patent